News

November 1, 2023

CONCUSSION DRUG STUDY SHOWS POSITIVE EARLY RESULTS

Study showed improvement in concussion symptoms in participants receiving OXE103. OXE103 pilot Phase 2a trial shows strong potential as an effective treatment for concussion. The […]

September 18, 2023

CUTISS launches Series C financing round to advance the development of its personalized skin technology, paving the way towards commercialization

Round C to finance the continued development and path to commercialization of denovoSkin™ and Viticell® Phase 2 clinical trial results for lead product denovoSkin™ reached […]

September 12, 2023

THE COMMUNICATIONS STRATEGY GROUP INC., A LIFE SCIENCES CONSULTANCY, ANNOUNCES TWO NEW ADVISORY BOARD MEMBERS REFLECTIVE OF FIRM’S GROWING GLOBAL PRACTICE

Professor Ruth V. Aguilera, PhD, Northeastern University, Trustee Professor at the D’Amore-McKim School of Business, Boston, Massachusetts, USA Mark Treherne, PhD, Chairperson, Monument Therapeutics, Cambridge, […]

August 3, 2023

Aardvark Therapeutics Announces Receipt of FDA Rare Pediatric Disease Designation for Prader-Willi Syndrome and Expands the Ongoing Phase 2 Clinical Trial

The FDA granted Aardvark Therapeutics a Rare Pediatric Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare genetic disease characterized by extreme […]